NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.230
0.00 (0.01%)
Nov 5, 2024, 1:10 PM EST - Market open
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 18 employees as of December 31, 2023. The number of employees increased by 4 or 28.57% compared to the previous year.
Employees
18
Change (1Y)
4
Growth (1Y)
28.57%
Revenue / Employee
n/a
Profits / Employee
-$544,333
Market Cap
23.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 118 |
| IRIDEX | 111 |
| Athira Pharma | 67 |
| Inspira Technologies Oxy B.H.N. | 42 |
| Palatin Technologies | 30 |
| iBio, Inc. | 16 |
| BioVie | 14 |
| Onconetix | 12 |
NRSN News
- 8 days ago - NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission - PRNewsWire
- 12 days ago - New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients - PRNewsWire
- 21 days ago - NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates - PRNewsWire
- 27 days ago - NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada - PRNewsWire
- 4 weeks ago - NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting - PRNewsWire
- 6 weeks ago - NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's - PRNewsWire
- 6 weeks ago - NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - PRNewsWire
- 2 months ago - NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire